Enara Bio (Group)

https://www.enarabio.com

Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as Dark Antigens™ and MR1-presented ligands. We are pioneering approaches to exploit these targets with TCR-directed T-cell immunotherapy and therapeutic vaccines. To achieve our mission, we are leveraging our differentiated Dark Antigen™ and TCR discovery platforms that integrate bioinformatics, immunopeptidomics, metabolomics and immunology in our Oxford, UK-based research lab. Enara Bio is backed by leading life science investors, including SV Health Investors. We have partnerships with world-class academic institutions, including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive the leading edge of these new areas of science. *

	Start	2020-06-03 renamed
	Predecessor	Ervaxx Ltd.
	Industry	cancer vaccine
	Industry 2	EDAPT™ platform (dark antigen identification)
	Person	Pojasek, Kevin (Ervaxx 201911 CEO)
	Person 2	Ashrafian, Houman (SV Health Investors 201810 Partner)

	Region	London, Greater London
	Country	United Kingdom (GB)
	City	n. a.
		Address record changed: 2021-01-12

Basic data	Employees	n. a.

		* Document for »About Section«: Boehringer Ingelheim. (1/12/21). "Press Release: Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies". Ingelheim, Oxford & London.

		Record changed: 2023-07-10